Detalles de la búsqueda
1.
[Frequency of antibodies against surface and nuclear antigens of hepatitis B virus in population of St. Petersburg in 2013].
Zh Mikrobiol Epidemiol Immunobiol
; (5): 43-9, 2014.
Artículo
en Ruso
| MEDLINE | ID: mdl-25536770
2.
[Long-term Efficacy and Safety of Sampeginterferon-ß1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results]. / Dolgosrochnye dannye po effektivnosti i bezopasnosti preparata sampeginterferon-ß1a u patsientov s remittiruyushchim rasseyannym sklerozom: rezul'taty 104-nedel'nogo randomizirovannogo dvoinogo slepogo klinicheskogo issledovaniya.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(2): 52-59, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-36843459
3.
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]. / Effektivnost' i bezopasnost' 48 nedel'nogo primeneniya monoklonal'nogo antitela protiv CD20 divozilimaba u patsientov s rasseyannym sklerozom: rezul'taty randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-4/MIRANTIBUS.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(7. Vyp. 2): 43-52, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-37560833
4.
[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2]. / Effektivnost' i bezopasnost' 24 nedel' primeneniya divozilimaba sredi patsientov s rasseyannym sklerozom v ramkakh randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-2.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(4): 37-47, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-37084363
5.
[Efficacy and safety of sampeginterferon ß-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial]. / Effektivnost' i bezopasnost' sampeginterferona ß-1a dlya lecheniya remittiruyushchego rasseyannogo skleroza: rezul'taty 52-nedel'nogo randomizirovannogo dvoinogo slepogo klinicheskogo issledovaniya.
Zh Nevrol Psikhiatr Im S S Korsakova
; 122(1): 62-71, 2022.
Artículo
en Ruso
| MEDLINE | ID: mdl-35175704
Resultados
1 -
5
de 5
1
Próxima >
>>